-
Investor Relations
- Corporate Governance
- Investor Presentations
- Annual Reports
- Compliance and AML
- Sustainability
- Financial Information
- Shareholders Toolkit
- FAQs
- Investors’ Queries
-
-
-
Accounts
- Al Hayrat Account
- Current Account
- Fixed Deposits Account
- Money Maker Account
- Salary Transfer Account
- Starmaker Account
- Super Saver Account
-
Al Wajaha
- Overview
-
BBK Lite
- Overview
-
NRI
- NRI Services
-
Debit Cards
- Classic
- Gold
- Signature
- Infinite
-
Self-service Banking
- ATM
- Deposit Machines
- Interactive Teller Machines
- Bank Certificates Issuance Machines
- Debit Card Issuance Machines
-
Foreign Exchange
- Remittance
- American Express
-
-
-
Insurance
- Home Secura
- Motor Secura
- Travel Secura
-
Investment
- Bonds
- IPO
- Mutual Funds
- Real Estate Investment
-
-
-
Branches and Self-Service
- Branches
- ATM
- Deposit Machines
- Debit Card Issuance Machines
- Corporate Deposit Machines
- Interactive Teller Machines
- Bank Certificates Issuance Machines
-
Contactless Payments
- Apple Pay
- Samsung Wallet
- Google Pay
- Garmin Pay
- Fitbit Pay
-
More Ways to Bank
- Mobile app & Online Banking
- eStatements
- BBK BanKey
- Corporate Deposit Card
- Debit Card
- Telebanking
- Open Banking
- AFAQ Payment System
- Remittance
- Visa Click to Pay
-
Sign Language
- Sign Language Directory
-
-
-
-
-
Accounts
- Business Current Account
- Business Fixed Deposit Account
-
Cash Management
- Bankey eBanking
- Payroll Services
- Deposit Machines
- POS Credimax
- Remittance
-
-
-
Working Capital Finance
- Overdraft
- Cheque discounting
- Short Term Loans
-
Long Term Finance
- Project Finance
- Assets Finance
- Real estate Finance
-
-
-
Corporate Banking
- Government Affairs
- Real Estate, Services and Trading
- Contracting, Building Material, and Manufacturing
-
International Banking
- Overview
- Services
- NRI
- Offshore Branches
- Representative offices
-
Enterprise Banking
- Overview
-
-
-
-
-
FINANCIAL NEWS
Oman-Neopharma issues OMR92mn in pharmaceutical plant
23 May 2017
(MENAFN) Neopharma, one of region’s pioneering pharmaceutical manufacturing firms, has invested OMR92mn towards diabetes management in the GCC and global markets.
Additionally, these investments involve OMR10mn in a state-of-the-art Japanese factory, OMR28mn in the acquisition of patents and licenses and an extra investment in clinical studies.
Moreover, Neopharma Japan has obtained a 65 percent share in the Japanese pharmaceutical firm, Cosmo ALA to produce this dietary supplement.
Accordingly, almost 422mn people are diabetic worldwide, while the number is projected to spiral to 642mn by 2040.
MENAFN2305201700450000ID1095502651
MENAFN2305201700450000ID1095502651
More News
08 Apr 2026
BBK awards over BD 1 Million to 273 winners in the February Al Hayrat Grand Prizes draw
01 Mar 2026
BBK activates partial remote working system for its workforce to ensure employee and customer safety and service continuity
24 Feb 2026
BBK discloses its financial results for the year ended 31st December 2025
05 Feb 2026
BBK announces December Al Hayrat Grand Prize winners and another wave of Grand prizes for February
This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more